Binding Term Sheet for the intended issuance of a convertible bond to the European Investment Bank (EIB) signed

EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action
   Marinomed Biotech AG: Binding Term Sheet for the intended issuance of a
   convertible bond to the European Investment Bank (EIB) signed

   27-Nov-2024 / 13:34 CET/CEST
   Disclosure of an inside information acc. to Article 17 MAR of the
   Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS
   Group AG.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

   Korneuburg, Austria, 27. November 2024 - Marinomed Biotech AG (the
   “Company”) announces that it has signed a binding term sheet with the
   European Investment Bank (EIB) for the intended issuance of a convertible
   bond (registered bond in the name or order) with a nominal value of EUR
   423,840, which is to be subscribed exclusively by the European Investment
   Bank (EIB) (excluding the statutory subscription rights of existing
   shareholders) against the contribution of a right of segregation. The
   convertible bond will evidence a conversion right in initially up to
   84,768 shares of the Company at a conversion price of EUR 5 per share and
   will be issued in December 2024. In the event of conversion of the
   convertible bond, it is intended to issue the shares available from the
   conditional capital of the Company. A corresponding report on the planned
   exclusion of the statutory subscription rights of existing shareholders to
   convertible bonds will be published shortly. The required resolution of
   the Supervisory Board on the issuance of the convertible bond with the
   exclusion of subscription rights can be adopted at the earliest two weeks
   after publication of the report. The necessary consent of the insolvency
   administrator for the issuance of the convertible bond has not yet been
   obtained. 

   +++ End of ad-hoc announcement +++ 
    

   End of Inside Information

   ══════════════════════════════════════════════════════════════════════════

   27-Nov-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com

   ══════════════════════════════════════════════════════════════════════════

   Language:    English
   Company:     Marinomed Biotech AG
                Hovengasse 25
                2100 Korneuburg
                Austria
   Phone:       +43 2262 90300
   E-mail:      office@marinomed.com
   Internet:    www.marinomed.com
   ISIN:        ATMARINOMED6
   WKN:         A2N9MM
   Listed:      Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
                Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
                (Official Market)
   EQS News ID: 2039579


    
   End of Announcement EQS News Service


   2039579  27-Nov-2024 CET/CEST